Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503-Reference-Cited by-同舟云学术

Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern Cooperative Oncology Group 3503

Published:2010-02 Issue:2 Volume:5 Page:169-178
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Amann Joseph M.,Lee Ju-Whei,Roder Heinrich,Brahmer Julie,Gonzalez Adriana,Schiller Joan H.,Carbone David P.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) (corrected);Fukuoka;J Clin Oncol,2003

2. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer);Thatcher;Lancet,2005

3. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

4. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer;Fong;J Thorac Oncol,2008

5. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer;Herbst;J Clin Oncol,2005

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the application of proteomics in lung cancer;Frontiers in Oncology;2022-09-27

2. A census of pathway maps in cancer systems biology;Nature Reviews Cancer;2020-02-17

3. Role of respiratory proteomics in precision medicine;Precision Medicine for Investigators, Practitioners and Providers;2020

4. The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy;European Journal of Cancer;2019-10

5. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer;The Oncologist;2018-08-23